Advances of Neoadjuvant Chemotherapy in Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

MOU Peng , LI Hongyuan.

Department of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

Corresponding author：

Keywords：

Breast cancer; Neoadjuvant chemotherapy

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo study the latest progress of neoadjuvant chemotherapy in breast cancer. MethodsLiteratures of neoadjuvant chemotherapy in breast cancer, involving with theoretical basis, clinical significance, indications, drugs, predictors, and its relationship of breastconserving surgery, sentinel lymph node biopsy were reviewed. ResultsNeoadjuvant chemotherapy could reduce the clinical stage, increase opportunity of breast-conserving surgery, learn the sensitivity of drugs, prevent distant metastases, but the impact of the sentinel lymph node biopsy was still in dispute. ConclusionNeoadjuvant chemotherapy is an important part of a systemic treatment for breast cancer, but how to select sensitive drugs, develop individualized treatment programs and forecast the outcome needs further study.

Citation： MOU Peng,LI Hongyuan.. Advances of Neoadjuvant Chemotherapy in Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2011, 18(9): 1011-1016. doi: Copy

1.	金贤英, 全贞玉, 韩春姬. 1999～2008年恶性肿瘤住院患者的疾病构成分析 [J]. 中国卫生统计, 2011, 28（1）: 107108.
2.	Bleyer A. Young adult oncology: the patients and their survival challenges [J]. CA Cancer J Clin, 2007, 57(4): 242255.
3.	Fisher B, Ravdin RG, Ausman RK, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation [J]. Ann Surg, 1968, 168(3): 337356.
4.	Frei E 3rd. Clinical cancer research: an embattled species [J]. Cancer, 1982, 50(10): 19791992.
5.	Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor [J]. Cancer Res, 1979, 39(10): 38613865.
6.	Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate [J]. Cancer Treat Rep, 1979, 63(1112): 17271733.
7.	Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [J]. Cancer Res, 1983, 43(4): 14881492.
8.	Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more [J]. J Natl Cancer Inst, 1990, 82(19): 15391545.
9.	Gianni L, Baselga J, Eiermann W, et al. Phase Ⅲ trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer [J]. J Clin Oncol, 2009, 27(15): 24742481.
10.	李卉, 廖传贵, 何小梅. 晚期乳腺癌新辅助化疗的临床报告 [J]. 中国普外基础与临床杂志, 2004, 11(1): 2021.
11.	张斌. 乳腺癌新辅助化疗的意义及其应用 [J]. 实用临床医药杂志, 2003, 7(2): 112114.
12.	Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre [J]. Ann Oncol, 1991, 2(5): 347354.
13.	张斌, 蔡玉娥, 张齐, 等. 新辅助化疗用于可手术乳腺癌的10年疗效 [J]. 中国肿瘤临床, 2002, 29(3): 157163.
14.	Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B18 [J]. J Natl Cancer Inst Monogr, 2001, (30): 96102.
15.	2010 NCCN乳腺癌临床实践指南(中国版) [EB/OL]. http://www.nccnasia.org/pdf/2010_BreastCancer_Ch.pdf.
16.	Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer [J]. Breast Dis, 20052006, 22: 6773.
17.	Dawood S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? [J]. Oncology (Williston Park), 2007, 21(6): 673679.
18.	任洪波, 王琦, 李少林, 等. 术前化疗结合放疗治疗炎性乳腺癌疗效分析 [J].中国肿瘤临床, 2006, 33(7): 384385.
19.	蔡海峰, 赵刚, 潘惠承. 新辅助化疗在隐匿性乳腺癌中的应用 [J]. 中国综合临床, 2006, 22(6): 538539.
20.	Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer [J]. N Engl J Med, 1976, 294(8): 405410.
21.	Erol K, Baltali E, Altundag K, et al. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5fluorouracil in locally advanced breast cancer [J]. Onkologie, 2005, 28(2): 8185.
22.	Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer:an overview of the randomised trials [J]. Lancet, 1998, 352(9132): 930942.
23.	Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B18 [J]. Cancer, 2002, 95(4): 681695.
24.	MouretReynier MA, Abrial CJ, Ferrière JP, et al. Neoadjuvant FEC 100 for operable breast cancer: eightyear experience at centre Jean perrin [J]. Clin Breast Cancer, 2004, 5(4): 303307.
25.	Liu MC, Demetri GD, Berry DA, et al. Doseescalation of filgrastim does not improve efficacy: clinical tolerability and longterm followup on calgb study 9 141 adjuvant chemotherapy for nodepositive breast cancer patients using doseintensified doxorubicin plus cyclophosphamide followed by [J]. Cancer Treat Rev, 2008, 34(3): 223230.
26.	Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP B28 [J]. J Clin Oncol, 2005, 23(16): 36863696.
27.	Boér K, Láng I, Juhos E, et al. Adjuvant therapy of breast cancer with docetaxelcontaining combination(TAC) [J]. Pathol Oncol Res, 2003, 9(3): 166169.
28.	Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy:updates of national surgical adjuvant breast and bowel project protocols B18 and B27 [J]. J Clin Oncol, 2008, 26(5): 778785.
29.	Andrade JM, Carrara HH, Pimentel FF, et al. Taxanebased chemotherapy enhances response to neoadjuvant treatment for stage Ⅱ and Ⅲ breast cancer [J]. Med Oncol, 2010 Oct 16. DOI: 10.1007/s1203201097110.
30.	Carmichael J. The role of gemcitabine in the treatment of other tumours [J]. Br J Cancer, 1998, 78 (Suppl 3): 2125.
31.	Estévez LG, SánchezRovira P, Dómine M, et al. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage Ⅱ and Ⅲ breast cancer patients: results of a phase Ⅱ study [J]. Clin Transl Oncol, 2007, 9(5): 317322.
32.	Yardley DA, Peacock NW, Dickson NR, et al. A phase Ⅱ trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer [J]. Clin Breast Cancer, 2010, 10(3): 217223.
33.	Ross JS, Fletcher JA, Linette GP, et al. The her2/neu gene and protein in breast cancer 2003: biomarker and target of therapy [J]. Oncologist, 2003, 8(4): 307325.
34.	Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2positive breast cancer [J]. N Engl J Med, 2005, 353(16): 16731684.
35.	Kulka J, Tokés AM, Tóth AI, et al. Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy [J]. Magy Onkol, 2009, 53(4): 335343.
36.	Chumsri S, Jeter S, Jacobs LK, et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and singleagent taxane with or without trastuzumab in stage Ⅱ/Ⅲ HER2positive breast cancer [J]. Clin Breast Cancer, 2010, 10(1): 4045.
37.	Bertelsen CA, Giuliano AE, Kern DH, et al. Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response [J]. J Surg Res, 1984, 37(4): 257263.
38.	Berry DA, Cirrincione C, Henderson IC, et al. Estrogenreceptor status and outcomes of modern chemotherapy for patients with nodepositive breast cancer [J]. JAMA, 2006, 295(14): 16581667.
39.	谢菲, 周波, 曹迎明, 等. 不同生物学标志物对乳腺癌新辅助化疗疗效的预测价值 [J]. 中国癌症杂志, 2010, 20（6）: 452456.
40.	Sullivan PS, Apple SK. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? [J]. Breast J, 2009, 15(2): 146154.
41.	Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triplenegative breast cancer patients [J]. Cancer Chemother Pharmacol, 2011, 67(4): 911917.
42.	王晓兰, 陈波, 姚凡, 等. HER2、p53的表达对乳腺癌蒽环类新辅助化疗疗效的影响 [J]. 山东医药, 2008, 48（32）: 13.
43.	Bao H, Yu D, Wang J, et al. Predictive value of serum antip53 antibodies, carcinoembryonic antigen, carbohydrate antigen 153, estrogen receptor, progesterone receptor and human epidermal growth factor receptor2 in taxanebased and anthracyclinebased neoadjuvant chemotherapy in locally advanced breast cancer patients [J]. Anticancer Drugs, 2008, 19(3): 317323.
44.	Zhu L, Li YF, Chen WG, et al. Her2 and topoisomerase iialpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients [J]. Chin Med J (Engl), 2008, 121(20): 19651968.
45.	Orlando L, Del Curto B, Gandini S, et al. Topoisomerase Ⅱalpha gene status and prediction of pathological complete remission after anthracyclinebased neoadjuvant chemotherapy in endocrine nonresponsive Her2/neupositive breast cancer [J]. Breast, 2008, 17(5): 506511.
46.	Ishitobi M, Komoike Y, Motomura K, et al. Early response to neoadjuvant chemotherapy in carcinoma of the breast predicts both successful breastconserving surgery and decreased risk of ipsilateral breast tumor recurrence [J]. Breast J, 2010, 16(1): 913.
47.	Fitzal F, Riedl O, Mittlbck M, et al. Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study [J]. Breast Cancer Res Treat, 2011, 127(1): 121128.
48.	Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma [J]. Cancer, 2000, 89(11): 21872194.
49.	Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients [J]. Ann Surg, 2009, 250(4): 558566.
50.	Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy [J]. Breast Cancer, 2007, 14(1): 1015.
51.	Ozmen V, Unal ES, Muslumanoglu ME, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy [J]. Eur J Surg Oncol, 2010, 36(1): 2329.

1. 金贤英, 全贞玉, 韩春姬. 1999～2008年恶性肿瘤住院患者的疾病构成分析 [J]. 中国卫生统计, 2011, 28（1）: 107108.
2. Bleyer A. Young adult oncology: the patients and their survival challenges [J]. CA Cancer J Clin, 2007, 57(4): 242255.
3. Fisher B, Ravdin RG, Ausman RK, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation [J]. Ann Surg, 1968, 168(3): 337356.
4. Frei E 3rd. Clinical cancer research: an embattled species [J]. Cancer, 1982, 50(10): 19791992.
5. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor [J]. Cancer Res, 1979, 39(10): 38613865.
6. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate [J]. Cancer Treat Rep, 1979, 63(1112): 17271733.
7. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [J]. Cancer Res, 1983, 43(4): 14881492.
8. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more [J]. J Natl Cancer Inst, 1990, 82(19): 15391545.
9. Gianni L, Baselga J, Eiermann W, et al. Phase Ⅲ trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer [J]. J Clin Oncol, 2009, 27(15): 24742481.
10. 李卉, 廖传贵, 何小梅. 晚期乳腺癌新辅助化疗的临床报告 [J]. 中国普外基础与临床杂志, 2004, 11(1): 2021.
11. 张斌. 乳腺癌新辅助化疗的意义及其应用 [J]. 实用临床医药杂志, 2003, 7(2): 112114.
12. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre [J]. Ann Oncol, 1991, 2(5): 347354.
13. 张斌, 蔡玉娥, 张齐, 等. 新辅助化疗用于可手术乳腺癌的10年疗效 [J]. 中国肿瘤临床, 2002, 29(3): 157163.
14. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B18 [J]. J Natl Cancer Inst Monogr, 2001, (30): 96102.
15. 2010 NCCN乳腺癌临床实践指南(中国版) [EB/OL]. http://www.nccnasia.org/pdf/2010_BreastCancer_Ch.pdf.
16. Kell MR, Morrow M. Surgical aspects of inflammatory breast cancer [J]. Breast Dis, 20052006, 22: 6773.
17. Dawood S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? [J]. Oncology (Williston Park), 2007, 21(6): 673679.
18. 任洪波, 王琦, 李少林, 等. 术前化疗结合放疗治疗炎性乳腺癌疗效分析 [J].中国肿瘤临床, 2006, 33(7): 384385.
19. 蔡海峰, 赵刚, 潘惠承. 新辅助化疗在隐匿性乳腺癌中的应用 [J]. 中国综合临床, 2006, 22(6): 538539.
20. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer [J]. N Engl J Med, 1976, 294(8): 405410.
21. Erol K, Baltali E, Altundag K, et al. Neoadjuvant chemotherapy with cyclophosphamide, mitoxantrone, and 5fluorouracil in locally advanced breast cancer [J]. Onkologie, 2005, 28(2): 8185.
22. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer:an overview of the randomised trials [J]. Lancet, 1998, 352(9132): 930942.
23. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the national surgical adjuvant breast and bowel (NSABP) protocol B18 [J]. Cancer, 2002, 95(4): 681695.
24. MouretReynier MA, Abrial CJ, Ferrière JP, et al. Neoadjuvant FEC 100 for operable breast cancer: eightyear experience at centre Jean perrin [J]. Clin Breast Cancer, 2004, 5(4): 303307.
25. Liu MC, Demetri GD, Berry DA, et al. Doseescalation of filgrastim does not improve efficacy: clinical tolerability and longterm followup on calgb study 9 141 adjuvant chemotherapy for nodepositive breast cancer patients using doseintensified doxorubicin plus cyclophosphamide followed by [J]. Cancer Treat Rev, 2008, 34(3): 223230.
26. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for nodepositive breast cancer: results from NSABP B28 [J]. J Clin Oncol, 2005, 23(16): 36863696.
27. Boér K, Láng I, Juhos E, et al. Adjuvant therapy of breast cancer with docetaxelcontaining combination(TAC) [J]. Pathol Oncol Res, 2003, 9(3): 166169.
28. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy:updates of national surgical adjuvant breast and bowel project protocols B18 and B27 [J]. J Clin Oncol, 2008, 26(5): 778785.
29. Andrade JM, Carrara HH, Pimentel FF, et al. Taxanebased chemotherapy enhances response to neoadjuvant treatment for stage Ⅱ and Ⅲ breast cancer [J]. Med Oncol, 2010 Oct 16. DOI: 10.1007/s1203201097110.
30. Carmichael J. The role of gemcitabine in the treatment of other tumours [J]. Br J Cancer, 1998, 78 (Suppl 3): 2125.
31. Estévez LG, SánchezRovira P, Dómine M, et al. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage Ⅱ and Ⅲ breast cancer patients: results of a phase Ⅱ study [J]. Clin Transl Oncol, 2007, 9(5): 317322.
32. Yardley DA, Peacock NW, Dickson NR, et al. A phase Ⅱ trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer [J]. Clin Breast Cancer, 2010, 10(3): 217223.
33. Ross JS, Fletcher JA, Linette GP, et al. The her2/neu gene and protein in breast cancer 2003: biomarker and target of therapy [J]. Oncologist, 2003, 8(4): 307325.
34. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2positive breast cancer [J]. N Engl J Med, 2005, 353(16): 16731684.
35. Kulka J, Tokés AM, Tóth AI, et al. Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy [J]. Magy Onkol, 2009, 53(4): 335343.
36. Chumsri S, Jeter S, Jacobs LK, et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and singleagent taxane with or without trastuzumab in stage Ⅱ/Ⅲ HER2positive breast cancer [J]. Clin Breast Cancer, 2010, 10(1): 4045.
37. Bertelsen CA, Giuliano AE, Kern DH, et al. Breast cancers: estrogen and progesterone receptor status as a predictor of in vitro chemotherapeutic response [J]. J Surg Res, 1984, 37(4): 257263.
38. Berry DA, Cirrincione C, Henderson IC, et al. Estrogenreceptor status and outcomes of modern chemotherapy for patients with nodepositive breast cancer [J]. JAMA, 2006, 295(14): 16581667.
39. 谢菲, 周波, 曹迎明, 等. 不同生物学标志物对乳腺癌新辅助化疗疗效的预测价值 [J]. 中国癌症杂志, 2010, 20（6）: 452456.
40. Sullivan PS, Apple SK. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma? [J]. Breast J, 2009, 15(2): 146154.
41. Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triplenegative breast cancer patients [J]. Cancer Chemother Pharmacol, 2011, 67(4): 911917.
42. 王晓兰, 陈波, 姚凡, 等. HER2、p53的表达对乳腺癌蒽环类新辅助化疗疗效的影响 [J]. 山东医药, 2008, 48（32）: 13.
43. Bao H, Yu D, Wang J, et al. Predictive value of serum antip53 antibodies, carcinoembryonic antigen, carbohydrate antigen 153, estrogen receptor, progesterone receptor and human epidermal growth factor receptor2 in taxanebased and anthracyclinebased neoadjuvant chemotherapy in locally advanced breast cancer patients [J]. Anticancer Drugs, 2008, 19(3): 317323.
44. Zhu L, Li YF, Chen WG, et al. Her2 and topoisomerase iialpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients [J]. Chin Med J (Engl), 2008, 121(20): 19651968.
45. Orlando L, Del Curto B, Gandini S, et al. Topoisomerase Ⅱalpha gene status and prediction of pathological complete remission after anthracyclinebased neoadjuvant chemotherapy in endocrine nonresponsive Her2/neupositive breast cancer [J]. Breast, 2008, 17(5): 506511.
46. Ishitobi M, Komoike Y, Motomura K, et al. Early response to neoadjuvant chemotherapy in carcinoma of the breast predicts both successful breastconserving surgery and decreased risk of ipsilateral breast tumor recurrence [J]. Breast J, 2010, 16(1): 913.
47. Fitzal F, Riedl O, Mittlbck M, et al. Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study [J]. Breast Cancer Res Treat, 2011, 127(1): 121128.
48. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma [J]. Cancer, 2000, 89(11): 21872194.
49. Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients [J]. Ann Surg, 2009, 250(4): 558566.
50. Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy [J]. Breast Cancer, 2007, 14(1): 1015.
51. Ozmen V, Unal ES, Muslumanoglu ME, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy [J]. Eur J Surg Oncol, 2010, 36(1): 2329.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Advances of Neoadjuvant Chemotherapy in Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content